Fulcrum Therapeutics Inc. (FULC) remains in focus as it advances multiple programs targeting genetically defined rare diseases. The company's lead candidate, pociredir, continues to progress through the Phase 1b PIONEER trial in sickle cell disease or SCD, with the 20 mg dose cohort currently underway.
Fulcrum has confirmed plans to share clinical data from this cohort by the end of 2025, following promising results from the earlier 12 mg group, which showed robust increases in fetal hemoglobin and improvements in key markers of hemolysis and anemia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com